Ofatumumab

ARZERRA, KESIMPTA

CD20-directed Cytolytic Antibody

NADAC/unit $24459.3201

No Shortage Tier 1: 17.3% PA Req: 71.7%

Ofatumumab targets CD20-positive cells to treat certain lymphomas and autoimmune conditions.

vs. brand ARZERRA: Generic saves up to -244493% per unit

Covered Lives

Explore in the Ecosystem

rxsaver.aiCompare prices for Ofatumumab drfinder.aiFind doctors who prescribe Ofatumumab rxbenefits.aiEmployer cost impact analysis clinicalrx.aiClinical profile: Ofatumumab

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.